Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Penicillin G Sodium

FDA-approved product (injectable, injection), marketed as Bicillin, Bicillin L-A, Permapen and 14 more.

Registered studies
50+
Lab records
18
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Penicillin G Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase sensitive penicillins; Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CE01; WHO ATC J01CE08; WHO ATC J01CE09; WHO ATC S01AA14

Repurposing investigation

Penicillin G Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA76.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli52.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae5.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis27.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 6 of 10 lab records
  • E. coli: measured active in 2 of 4 lab records
  • K. pneumoniae: measured active in 0 of 4 lab records
Open Penicillin G Sodium in ChEMBL Registered studies below
Show the 18 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Penicillin G Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD

    NCT02407119 · start 2003-06

    Registered record
    Registry ID
    NCT02407119
    Conditions
    Helicobacter Pylori Infection; Early Gastric Cancer; Endoscopic Resection
    Interventions
    7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin; Placebo, Omeprazole or Rabeprazole, Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2003-06
    Completion
    2030-06
    Enrolment
    470

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Early Gastric Cancer; Endoscopic Resection
    Intervention7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin; Placebo, Omeprazole or Rabeprazole, Clarithromycin
    PhasePhase 3
    Registry statusActive not recruiting

  • Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy

    NCT01792700 · start 2003-01

    Registered record
    Registry ID
    NCT01792700
    Conditions
    Helicobacter Infections
    Interventions
    esomeprazole; tripotassium dicitrate bismuthate; metronidazole; tetracycline; moxifloxacin; amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-01
    Completion
    2010-12
    Enrolment
    648

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Infections
    Interventionesomeprazole; tripotassium dicitrate bismuthate; metronidazole; tetracycline +2 more
    PhasePhase 4
    Registry statusCompleted

  • Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

    NCT00195533 · start 2001-07

    Registered record
    Registry ID
    NCT00195533
    Conditions
    Hematological Malignancy; Leukemia; Myelodysplasia; Lymphoma; Myeloma; Stem Cell Transplantation
    Interventions
    piperacillin-tazobactam; glycopeptide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-07
    Completion
    2005-03
    Enrolment
    801

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematological Malignancy; Leukemia; Myelodysplasia; Lymphoma +2 more
    Interventionpiperacillin-tazobactam; glycopeptide
    PhaseNot recorded
    Registry statusCompleted

  • Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma

    NCT00201422 · start 1996-06

    Registered record
    Registry ID
    NCT00201422
    Conditions
    MALT Lymphoma
    Interventions
    Omeprazole, Amoxicillin, Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1996-06
    Completion
    2004-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMALT Lymphoma
    InterventionOmeprazole, Amoxicillin, Clarithromycin
    PhaseNot applicable
    Registry statusCompleted

  • Acupuncture and Herbal Treatment of Chronic HIV Sinusitis

    NCT00002149

    Registered record
    Registry ID
    NCT00002149
    Conditions
    HIV Infections; Sinusitis
    Interventions
    Clavulanate potassium; Pseudoephedrine hydrochloride; Amoxicillin trihydrate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Sinusitis
    InterventionClavulanate potassium; Pseudoephedrine hydrochloride; Amoxicillin trihydrate
    PhaseNot applicable
    Registry statusCompleted